GRI Bio, Inc. (GRI) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

34/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

41

Fair Value

Momentum

17

Strong Down

Sentiment

58

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: W. Marc Hertz
Listed since: Feb 10, 2021
Employees: 4

Market position

Day range

Current $1.65

$1.65$1.72

52-week range

Current $1.65

$1.36$80.36

Open: $1.72
Previous close: $1.67
Volume: 83.15K; 0.6× average
Average volume: 138.37K; Average daily volume
Market cap: 148.22K USD
Beta: -0.66; Market reference 1
50-day average: $1.7298; -4.61% below average
200-day average: $9.4267; -82.50% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: -7.48M USD
P/E (TTM): -0.04×
P/B (TTM): 0.29×
P/S (TTM): 0×
EV / EBITDA: 0.62×
Earnings yield: -1762.64%
Free cash flow yield: -1502.14%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -199.00%
Return on assets: -137.96%
Return on invested capital: -197.02%

Financial health

Debt / equity: 0×
Current ratio: 3.25×
Altman Z-score: -8.45
Piotroski F-score: 1 of 9

Financial statements

Income trends

Operating income

−11.98M USD-45.44%

Net income

−11.96M USD-45.68%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	6.82M USD	3.77M USD	3.23M USD	242K USD	249K USD
Selling, general, and administrative	5.16M USD	4.47M USD	8.16M USD	2M USD	813K USD
Operating expenses	11.98M USD	8.24M USD	11.39M USD	2.24M USD	1.06M USD
Interest income	21K USD	25K USD	—	—	—
Interest expense	—	—	2.08M USD	653K USD	547K USD
Depreciation and amortization	4K USD	4K USD	4K USD	3K USD	3K USD
Operating income	−11.98M USD	−8.24M USD	−11.39M USD	−2.24M USD	−1.06M USD
Net income	−11.96M USD	−8.21M USD	−13.04M USD	−3.22M USD	−1.56M USD